BMC to try out hydroxychloroquine as prophylaxis in Dharavi, Worli Koliwada

April 14, 2020 03:31 am | Updated 03:34 am IST - Mumbai

The Brihanmumbai Municipal Corporation (BMC), in an attempt to arrest the spread of COVID-19 in slums, plans to roll out the anti-malarial drug, hydroxychloroquine, as prophylaxis — a treatment course administered to prevent a disease — for the community. The first-of-its-kind pilot project will be implemented in Dharavi and Worli Koliwada this week.

Additional municipal commissioner Suresh Kakani on Monday told The Hindu that medical experts from the All India Institute of Medical Sciences and NITI Aayog had given a green signal for the pilot.

“At present, 50,000 people are in the containment areas of Dharavi and Worli Koliwada each. We are planning to target the population in the containment areas in the age group of 18 to 55, but without any underlying ailments like diabetes and hypertension,” Mr. Kakani said.

Due to the global interest in the drug, there are concerns of a possible shortage in India. But civic officials said Mumbai had enough stock as of now. “We have 10 lakh tablets available. We are prepared to start the pilot in a day or two,” Mr. Kakani said.

Minor details of the project are being worked out. “It is a seven-week-long course. Our community health volunteers will be roped in to distribute the drug to the target population,” he said.

Hydroxychloroquine is also prescribed for patients with arthritis and lupus. The national task force set up for the novel coronavirus by the Indian Council of Medical Research has recommended the use of the drug as prophylaxis for asymptomatic healthcare workers involved in the treatment of positive COVID-19 patients as well as asymptomatic household contacts of positive patients.

But experts said there was a lack of robust data on the drug’s efficacy as treatment or prophylaxis against COVID-19.

“The drug is not without side effects. A baseline ECG is a must before putting people on this drug as it may have cardiotoxic effects,” said a Mumbai-based infectious disease specialist, adding the BMC’s rationale behind the community pilot is that “we don’t have many options to stop the spread.”

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.